Regado Biosciences raises $20M in a private placement Under the agreement, the investors will purchase an aggregate of 4 million shares of common stock at a purchase price of $5.00 per share. The net proceeds of the offering are expected to be used for general corporate and working capital purposes, including the ongoing Phase 3 REGULATE-PCI clinical trial. Cowen and Company acted as the lead placement agent for the offering, and BMO Capital Markets acted as co-placement agent.
News For RGDO From The Last 14 Days
Check below for free stories on RGDO the last two weeks.